RIGL Rigel Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: RIGL

Price (delayed)

$48.13

Market cap

$899.06M

P/E Ratio

2.7

Dividend/share

N/A

EPS

$17.83

Enterprise value

$878.2M

Sign up for free to view scoring metrics ?
Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 99

Rigel Pharmaceuticals, Inc. is a clinical-stage drug development company. The Company discovers and develops small-molecule drugs for the treatment of inflammatory and autoimmune diseases, as well as muscle disorders. Its ...

Highlights
RIGL's debt is down by 35% YoY and by 13% QoQ
RIGL's equity is up by 6% from the previous quarter
The company's gross profit fell by 10% QoQ but it rose by 3.2% YoY
Rigel Pharmaceuticals's revenue has decreased by 8% QoQ but it has increased by 3.3% YoY
The quick ratio has contracted by 28% from the previous quarter and by 8% YoY
Rigel Pharmaceuticals's EPS has decreased by 12% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://www.rigel.com
Peers: AZN AMGN

Key stats

What are the main financial stats of RIGL

RIGL stock price

How has the Rigel Pharmaceuticals stock price performed over time
Intraday
-1.41%
1 week
8.21%
1 month
4.88%
1 year
41.48%
YTD
12.37%
QTD
23.03%

Financial performance

How have Rigel Pharmaceuticals's revenue and profit performed over time
Revenue
$276.79M
Gross profit
$252.95M
Operating income
$87.05M
Net income
$321.91M
Gross margin
91.4%
Net margin
116.3%
RIGL's operating income is down by 30% since the previous quarter and by 17% year-on-year
The operating margin has contracted by 24% from the previous quarter and by 19% YoY
The net income has declined by 12% since the previous quarter
The company's gross profit fell by 10% QoQ but it rose by 3.2% YoY

Price vs fundamentals

How does RIGL's price correlate with its fundamentals

Growth

What is Rigel Pharmaceuticals's growth rate over time

Valuation

What is Rigel Pharmaceuticals stock price valuation
RIGL P/E details
P/E
2.7
P/B
2.09
P/S
3.22
EV/EBIT
9.61
EV/EBITDA
9.34
EV/Sales
3.17
Rigel Pharmaceuticals's EPS has decreased by 12% QoQ
The stock's price to earnings (P/E) is 10% more than its last 4 quarters average of 2.5
The price to book (P/B) is 8% less than the last 4 quarters average of 2.3
RIGL's equity is up by 6% from the previous quarter
The stock's price to sales (P/S) is 49% more than its last 4 quarters average of 2.2 and 42% more than its 5-year quarterly average of 2.3
Rigel Pharmaceuticals's revenue has decreased by 8% QoQ but it has increased by 3.3% YoY

Efficiency

How efficient is Rigel Pharmaceuticals business performance
The ROE has dropped by 78% year-on-year and by 34% since the previous quarter
RIGL's return on invested capital has dropped by 77% year-on-year and by 41% since the previous quarter
The return on assets has declined by 27% since the previous quarter but it rose by 27% year-on-year
Rigel Pharmaceuticals's return on sales has decreased by 23% QoQ and by 17% YoY

Dividends

What is RIGL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for RIGL.

Financial health

How did Rigel Pharmaceuticals financials performed over time
Rigel Pharmaceuticals's total assets has soared by 152% YoY and by 3.3% from the previous quarter
The quick ratio has contracted by 28% from the previous quarter and by 8% YoY
RIGL's debt is 91% lower than its equity
RIGL's debt to equity has shrunk by 88% YoY and by 18% QoQ
RIGL's debt is down by 35% YoY and by 13% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.